Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Estimated fair value of equity securities		$ 45,616		$ 41,937
Unrealized gain (loss) on equity securities		$ 3,679	$ (6,992)
Vaxcyte, Inc. | Vaxcyte Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares held		667,780		667,780
Estimated fair value of equity securities		$ 45,600		$ 41,900
Unrealized gain (loss) on equity securities		$ 3,700	$ (7,000)
Blackstone Life Sciences | Royalty | 2015 License Agreement
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Revenue interest percentage	4.00%	4.00%